Pathkey.ai Ltd (AU:PKY) — Market Cap & Net Worth
Market Cap & Net Worth: Pathkey.ai Ltd (PKY)
Pathkey.ai Ltd (AU:PKY) has a market capitalization of $332.70 (AU$470.20) as of May 2, 2026. Listed on the AU stock exchange, this Australia-based company holds position #31459 globally and #1834 in its home market, demonstrating a 66.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pathkey.ai Ltd's stock price AU$0.05 by its total outstanding shares 9404 (9.40K). Analyse Pathkey.ai Ltd cash conversion from operations to see how efficiently the company converts income to cash.
Pathkey.ai Ltd Market Cap History: 2025 to 2026
Pathkey.ai Ltd's market capitalization history from 2025 to 2026. Data shows growth from $106.46 to $332.70 (0.00% CAGR).
Pathkey.ai Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pathkey.ai Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Pathkey.ai Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $106.46 | $27.78K | -$1.45 Million | 0.00x | N/A |
Competitor Companies of PKY by Market Capitalization
Companies near Pathkey.ai Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Pathkey.ai Ltd by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #926 globally with a market cap of $28.21 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #2225 globally with a market cap of $10.06 Billion USD ( AU$14.22 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2339 globally with a market cap of $9.34 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2447 globally with a market cap of $8.82 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #926 | Veeva Systems Inc Class A | NYSE:VEEV | $28.21 Billion | $171.60 |
| #2225 | Pro Medicus Ltd | AU:PME | $10.06 Billion | AU$136.16 |
| #2339 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $9.34 Billion | $55.00 |
| #2447 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $8.82 Billion | $52.58 |
Pathkey.ai Ltd Historical Marketcap From 2025 to 2026
Between 2025 and today, Pathkey.ai Ltd's market cap moved from $106.46 to $ 332.70, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$332.70 | +212.50% |
| 2025 | AU$106.46 | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Pathkey.ai Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $332.70 USD |
| MoneyControl | $332.70 USD |
| MarketWatch | $332.70 USD |
| marketcap.company | $332.70 USD |
| Reuters | $332.70 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pathkey.ai Ltd
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The com… Read more